29. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008;26(May 20 suppl):abstr 2010b. 30. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothe- lial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413–2419. 31. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xeno- grafts. Cancer Res. 2001;61(1):39–44. 32. Lai A, Filka E, McGibbon B, Nghiemphu PL, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radia- tion therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372–1380. 33. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell. 2007;11(1):83–95. 34. Saishin Y, Saishin YTakahasi K, et al. VEGF-TRAP R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241–248. 35. Konner J, Dupont J. Use of soluble recombinant decoy receptor vas- cular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer. 2004;4 Suppl 2:S81–85. 36. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002;99(17):11393–11398. 37. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67(5):1526–1537. 38. De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol. 2008;26(May 20 suppl): abstr 2020. 39. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery. 2004;55(2):426–432; discussion 432. 40. Yung WKA, Friedman H, Conrad C, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibi- tor, in patients with recurrent glioblastoma multiforme. Proceedings of the American Society of Clinical Oncology Meeting. Chicago, USA. 2003. Abstract 395. 41. Conrad C, Friedman H, Reardon D. A Phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1512. 42. Reardon D, Friedman H, Yung WKA, et al. A phase I/II trial of PTK787/ ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combina- tion with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1513. 43. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51(8):2164–2172. 44. Pelloski CE, Zhang L, Lin E, et al. EGFRvIII status deﬁnes distinct subtypes of glioblastoma: an analysis of 649 cases. Proceedings of the Eleventh Annual Meeting of the Society for Neuro-Oncology. Orlando, USA. 2006. Abstract PA-26. 45. Rich JN, Reardon DA, Peery T, et al. Phase II trial of geﬁtinib in recur- rent glioblastoma. J Clin Oncol. 2004;22(1):133–142. Biologics:Targets & Therapy 2009:3 Malignant gliomas 46. Uhm JH, Ballman KV, Giannini C, et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1505. 47. Lieberman FS, Cloughesy T, Fine H, et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable menin- giomas. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans USA. 2004. Abstract 1510. 48. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67–78. 49. Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma mutliforme: Interim results. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1558. 50. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI- 774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1502. 51. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012–2024. 52. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880–887. 53. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet- derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60(18):5143–5150. 54. Geng L, Shinohara ET, Kim D, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys. 2006;64(1):263–271. 55. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res. 2006;12(16):4899–4907. 56. Dresemann G. Imatinib and hydroxyurea in pretreated pro- gressive glioblastoma multiforme: a patient series. Ann Oncol. 2005;16(10):1702–1708. 57. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma mul- tiforme. J Clin Oncol. 2005;23(36):9359–9368. 58. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007;83(1):53–60. 59. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (Berl). 2004;108:467–470. 60. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430. 61. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipi- farnib in patients with recurrent malignant glioma either receiv- ing or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24(22):3651–3656. 62. Gilbert MR, Gaupp P, Liu V, et al. A phase I study of temozolo- mide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. Proceedings of the American Society of Clinical Oncology Meeting. Atlanta, USA. 2006. Abstract 1556. 63. Sathornsumetee S, Hjelmeland AB, Keir ST, et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006;66(17):8722–8730. 64. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic signiﬁcance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926–1933. 23